PRNewsWire
30 Sept 2026, 05:00 UTC · 2h ago
Verdict
Headline takes no side. We score ABBV +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
AbbVie is presenting primary results from the Phase 2 APEX Part B dose-regimen-finding study for zumilokibart in moderate-to-severe atopic dermatitis.
Newannounced today, Sept 30
So whatPositive Phase 2 primary results typically trigger the initiation of Phase 3 trials within the next 6-12 months.
More positive than 79% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
AbbVie will present late-breaking data on lutikizumab's ability to target neutrophilic inflammation and fibroblast activation in hidradenitis suppurativa.
Newannounced today, Sept 30
More positive than 66% of claims this week
The company is disclosing Week 76 efficacy and safety data for upadacitinib in adults and adolescents with non-segmental vitiligo.
Newannounced today, Sept 30
So whatLong-term durability data (76 weeks) is critical for securing insurance reimbursement and long-term prescription stability.
More positive than 54% of claims this week
Week 52 results from the Phase 3 UP-AA clinical trial program for upadacitinib in severe alopecia areata will be presented.
Newannounced today, Sept 30
More positive than 54% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company is showcasing a strong dermatology portfolio with positive new clinical and real-world evidence across multiple therapies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
2h ago
—
ABBV hasn't traded since this ran. Last close $263.25 (Sep 29); the reaction starts at the next open.
ABBV chart →
